Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953545 | 0.83 | PDE4B (0.42) | KCNH2SCN8ASCN10ASLC6A4PDE4D | |
| SCHEMBL12952665 | 0.82 | SCN8A (0.43) | KCNH2SCN8ASCN10ASLC6A4PDE4D | |
| SCHEMBL12952904 | 0.82 | SCN8A (0.43) | KCNH2SCN8ASCN10ASLC6A4PDE4D | |
| SCHEMBL7650939 | 0.81 | SLC6A4 (0.42) | TACR1KCNH2SCN8ASCN10ASLC6A4 | |
| SCHEMBL6207509 | 0.81 | TACR1 (0.41) | TACR1KCNH2SCN8ASCN10ASLC6A4 | |
| SCHEMBL14894454 | 0.80 | TACR1 (0.41) | TACR1KCNH2SCN8ASCN10ASLC6A4 | |
| SCHEMBL6201255 | 0.77 | EPHX2 (0.43) | TACR1KCNH2SCN8ASCN10ASLC6A4 | |
| SCHEMBL7645001 | 0.77 | TACR1 (0.39) | TACR1KCNH2SCN8ASCN10ASLC6A4 | |
| SCHEMBL6482510 | 0.77 | TACR1 (0.48) | TACR1KCNH2SCN8ASCN10ASLC6A4 | |
| SCHEMBL12953108 | 0.77 | NTRK1 (0.38) | KCNH2SLC6A4PDE4DSCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942733-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2005-04-27 | — | — | EP | disclosed |
| EP-0941093-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME (GB) | 2005-02-09 | — | — | EP | disclosed |
| EP-0941092-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2004-12-29 | — | — | EP | disclosed |
| EP-0942732-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS | MERCK SHARP & DOHME (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6613765-B1 | Administering compounds such as 2-(1-(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4 -triazolo)methyl)morpholine; sustained release antidepressants with side effect reduction | MERCK SHARP & DOHME LIMITED | 2003-09-02 | — | — | US | disclosed |
| US-6271230-B1 | ADMINISTERING NEUROKININ RECEPTOR ANTAGONIST | MERCK SHARP & DOHME LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| US-6214846-B1 | TREATING INFLAMMATION, MIGRAINE, EMESIS, POSTHERPETIC NEURALGIA, DEPRESSION OR ANXIETY | MERCK SHARP & DOHME LIMITED | 2001-04-10 | — | — | US | disclosed |
| US-6156749-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LIMITED (GB) | 2000-12-05 | — | — | US | disclosed |
| US-6114315-A | ORAL ADMINISTERING; SIDE EFFECT REDUCTION | MERCK SHARP & DOHME LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| US-6100256-A | ORALLY ADMINISTERING AN ORALLY ACTIVE, LONG ACTING, CENTRAL NERVOUS SYSTEM-PENETRANT NK-1(NEUROKININ-1, SUBSTANCE P) RECEPTOR ANTAGONIST; FOR PATIENT WHO IS NON-RESPONSIVE TO, OR FOR WHOM ANTIPSYCHOTIC AGENTS ARE CONTRAINDICATED | MERCK SHARP & DOHME LTD. (GB) | 2000-08-08 | — | — | US | disclosed |
| WO-1999000368-A1 | SUBSTITUTED 3-(BENZYLAMINO)PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998024447-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024443-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024445-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SCHIZOPHRENIC DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024444-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SUBSTANCE USE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024439-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024442-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEXUAL DYSFUNCTION | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024446-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024438-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024440-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING STRESS DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |